Shopping Cart
Remove All
Your shopping cart is currently empty
KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. Furthermore, when administered at 50 µM, KSL-128114 elevates survival times in a patient-derived xenograft (PDX) mouse model of GBM, where mice were implanted intracranially with patient-derived GBM cells pre-cultured with KSL-128114.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $55 | Inquiry | Inquiry | |
| 5 mg | $244 | Inquiry | Inquiry | |
| 10 mg | $428 | Inquiry | Inquiry | |
| 25 mg | $939 | Inquiry | Inquiry |
| Description | KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. Furthermore, when administered at 50 µM, KSL-128114 elevates survival times in a patient-derived xenograft (PDX) mouse model of GBM, where mice were implanted intracranially with patient-derived GBM cells pre-cultured with KSL-128114. |
| Synonyms | Ac-rRrGrKkRrSHWX1X2DI-OH (X1=tert-Leucine; X2=Cyclohexylglycine) |
| Molecular Weight | 2201.60 |
| Formula | C96H165N39O21.XCF3COOH |
| Sequence | Ac-D-Arg-Arg-D-Arg-Gly-D-Arg-Lys-D-Lys-Arg-D-Arg-Ser-His-Trp-Gly(tBu)-Chg-Asp-Ile-OH.TFA |
| Sequence Short | RRRGRKKRRSHWXXDI |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: 1 mg/mL (0.45 mM), Sonication is recommended. PBS pH 7.2: 10 mg/mL (4.54 mM), Sonication is recommended. DMF: 1 mg/mL (0.45 mM), Sonication is recommended. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.